Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2023 | PANAMA: addition of maintenance panitumumab does not affect QoL in mCRC

Alexej Ballhausen, MD, Charité, Berlin, Germany, shares health-related quality of life (QoL) results of patients enrolled in the randomized PANAMA trial (NCT01991873), which evaluated fluorouracil and folinic acid with or without panitumumab as maintenance therapy following first-line panitumumab and FOLFOX alone in RAS wild-type metastatic colorectal cancer (mCRC). Addition of panitumumab in the maintenance setting significantly improved progression free-survival and did not impact QoL. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript (edited for clarity)

We are pleased to be at this year year’s ASCO GU 2023 to present health-related quality of life from the PANAMA trial. This is of a randomized phase II open-label trial investigating the addition of panitumumab to 5FU and folinic acid as maintenance therapy in RAS wild-type metastatic colorectal cancer following a first line induction therapy with six cycles of FOLFOX and panitumumab...

We are pleased to be at this year year’s ASCO GU 2023 to present health-related quality of life from the PANAMA trial. This is of a randomized phase II open-label trial investigating the addition of panitumumab to 5FU and folinic acid as maintenance therapy in RAS wild-type metastatic colorectal cancer following a first line induction therapy with six cycles of FOLFOX and panitumumab.

The study met its primary endpoint and demonstrated a superior progression-free survival with the addition of panitumumab as maintenance therapy, and we investigated the health related quality of life in this study in a longitudinal fashion. We used the EORTC QLQ-C30 questionnaire during each cycle of therapy. Main health related quality of life outcomes were mean changes in the respective items of that questionnaire, as well as individual changes for each patient and cycle of therapy.

Of note, during baseline, there was no significant difference between patients that were randomized into the trial after induction and those who were not. However, looking into mean changes between baseline and six cycles of induction therapy, we find that the health-related quality of life develops numerically favorably for patients who were subsequently randomized into the trial.

(01:41)
In the maintenance therapy phase of the trial, we focused on both treatment groups of patients that received 5FU folinic acid plus panitumumab and those who received 5FU folinic acid alone. What we found is that mean changes from baseline in health-related quality of life items, they developed quite in the same fashion in both treatment arms, and in the individual changes, we found some numerical differences that favored patient groups that received 5FU and folinic acid alone. So, taken together, our results taking into perspective the PFS benefit, might help inform individual clinical decision making.

Read more...